Back to search results

Cagrilintide for Overweight and Obesity in People Who Cannot Tolerate GLP-1 Therapies

This study is looking at how well people with overweight or obesity can tolerate Cagrilintide, a new medication, compared to a placebo (an inactive treatment). It's for individuals who have had to stop taking GLP-1 receptor agonist (GLP-1 RA) medications due to stomach or gut side effects. You would receive either Cagrilintide or placebo by injection under the skin, decided by chance. The main goal is to see what percentage of participants can take Cagrilintide at a standard or higher dose after 26 weeks. The study plans to enroll 114 participants and will last about 8 months. The current recruitment status is unclear.

Study design
This is an interventional study where participants are randomly assigned to receive either Cagrilintide or a placebo. It aims to enroll 114 participants.
What's involved
You would receive Cagrilintide or placebo injections under the skin. The study will last for about 8 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at week 26, which is about 6 months into the 8-month study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07607587

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Recruiting
PHASE1Ages 18+InterventionalTreatment
Novo Nordisk A/S
~114 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:CagrilintidePlacebo (matched to Cagrilintide)

At a glance

Recruiting sites
10 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo
Measured over At week 26

Conditions

Obesity
Overweight

Explore related trials

Obesity

Where it's being run

11 sites across 6 states
Florida4
North Carolina2
Texas2
California1
South Carolina1
Tennessee1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth)
Age 18 years or above at the time of signing the informed consent
History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2)

Exclusion

Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
History of type 1 or type 2 diabetes
Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening
Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening
Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening

What this trial measures

  • Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placeboAt week 26

    Measured as percentage of participants.